Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942118 | 0.87 | KDM4E (0.51) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL11078200 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL4254800 | 0.74 | CYP19A1 (0.50) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL13935969 | 0.72 | GPR84 (0.49) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL19230419 | 0.72 | DNMT1 (0.83) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL12236188 | 0.70 | DNMT1 (0.67) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL7122517 | 0.70 | DNMT1 (0.73) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL19230420 | 0.70 | DNMT1 (0.73) | KDM4EALDH1A1NPC1GAAMAPT | |
| SCHEMBL16144677 | 0.70 | DNMT1 (0.80) | KDM4EALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30362207 | 0.70 | DNMT1 (0.67) | KDM4EALDH1A1NPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121510-B | Naphthofuran o-quinone compound, preparation method and application thereof, antitumor pharmaceutical composition and antibacterial pharmaceutical composition | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2023-04-14 | — | — | CN | disclosed |
| CN-108947948-B | N-aryl naphthofuranone imine compound and synthetic method thereof | 湖南大学 | 2021-07-20 | — | — | CN | disclosed |
| CN-113121510-A | Naphthofuran o-quinone compound, preparation method and application thereof, antitumor pharmaceutical composition and antibacterial pharmaceutical composition | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2021-07-16 | — | — | CN | disclosed |
| US-20210161855-A1 | 5-LIPOXYGENASE ANTAGONISTS | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2021-06-03 | — | — | US | disclosed |
| EP-3678657-A1 | 5-LIPOXYGENASE ANTAGONISTS | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019050422-A1 | 5-LIPOXYGENASE ANTAGONISTS | INSTITUTO DE MEDICINA MOLECULAR (PT) | 2019-03-14 | — | — | WO | disclosed |
| WO-2017079864-A1 | TREATMENT OF CANCERS RELATED TO CHRONICALLY ACTIVE RAS | HANGZHOU YIER BIOTECH CO., LTD. (CN) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017079864-A1 | TREATMENT OF CANCERS RELATED TO CHRONICALLY ACTIVE RAS | HANGZHOU YIER BIOTECH CO., LTD. (CN) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017070012-A1 | LAPACHONE DERIVATIVES CONTAINING TWO REDOX CENTERS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9422231-B2 | Method for inhibiting Trypanosoma cruzi | HOWARD UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2427057-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
| JP-2006290871-A | COMPOUND EXHIBITING ANTI-CANCER PROPERTY, INTERMEDIATE THEREFOR AND METHOD FOR PRODUCING THE SAME | TAHEEBO JAPAN KK | 2006-10-26 | — | — | JP | disclosed |
| EP-0888326-B1 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RES FOUND (US) | 2006-08-16 | — | — | EP | disclosed |
| US-5969163-A | CONTACTING SOLUTION OF LAWSONE IN DIMETHYL SULFOXIDE AT LOW TEMPERATURE WITH LITHIUM HYDRIDE AND WARMING TO FORM LITHIUM SALT, ALKYLATING WITH ALLYL HALIDE IN PRESENCE OF LITHIUM IODIDE, CYCLIZING ALKYLATED LAWSONE DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0888326-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5824700-A | ANTICARCINOGENIC AGENTS FOR TREATING BREAST CANCER OR COLON CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-10-20 | — | — | US | disclosed |
| WO-1997031936-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | NR2C2, NR0B2, NR4A2 | KDM4E 3707/4885ALDH1A1 862/4885NPC1 2995/4885 |
| US-20210161855-A1 | 5-LIPOXYGENASE ANTAGONISTS | ALOX5, ALOX15, ALOX15B | KDM4E 1552/4885ALDH1A1 299/4885NPC1 3178/4885 |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | PDF, EIF5B, EIF4E | KDM4E 169/4885ALDH1A1 3464/4885NPC1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.